BDX (Becton, Dickinson and Co.)
Insider Trading Activity
Every open-market purchase and sale reported by BDX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-06 | Robert Luther Huffines | Director | A | — | — |
| 2026-08-06 | Carrie L Byington | Director | A | — | — |
| 2026-07-28 | Michael Feld | EVP, Chief Revenue Officer | Sell | — | — |
| 2026-07-06 | Bilal Muhsin | EVP & President Connected Care | MIXED | — | — |
| 2026-06-26 | Michael Feld | EVP, Chief Revenue Officer | Sell | — | — |
| 2026-06-25 | Michael David Garrison | EVP & Pres Med.Essntl&BioPharm | Sell | — | — |
| 2026-06-11 | Michael David Garrison | EVP & Pres Med.Essntl&BioPharm | Sell | — | — |
| 2026-06-03 | Thomas E Jr Polen | Chairman, CEO and President | MIXED | — | — |
| 2026-06-02 | Peter Menziuso | EVP and President, BDI | A | — | — |
| 2026-05-27 | Michael Feld | EVP, Chief Revenue Officer | Sell | — | — |
| 2026-05-08 | Vitor Roque | EVP & Chief Financial Officer | A | — | — |
| 2026-05-08 | Carrie L Byington | Director | A | — | — |
| 2026-05-08 | Robert Luther Huffines | Director | A | — | — |
| 2026-04-28 | Michael Feld | EVP, Chief Revenue Officer | Sell | — | — |
| 2026-04-06 | Shana Carol Neal | EVP and Chief People Officer | F | — | — |
| 2026-03-27 | Michael Feld | EVP, Chief Revenue Officer | Sell | — | — |
| 2026-03-17 | Lanesha Minnix | EVP and General Counsel | A | — | — |
| 2026-03-04 | Pamela L. Spikner | SVP Controller & CAO | A | — | — |
| 2026-03-04 | Vitor Roque | Interim CFO | A | — | — |
| 2026-02-27 | Michael Feld | EVP, Chief Revenue Officer | Sell | — | — |
| 2026-02-18 | BERTRAM L SCOTT | Director | Sell | — | — |
| 2026-02-05 | Christopher Ian Montague Jones | Director | A | — | — |
| 2026-02-05 | Carrie L Byington | Director | A | — | — |
| 2026-02-05 | Robert Luther Huffines | Director | A | — | — |
| 2026-01-29 | Jacqueline Wright | Director | A | — | — |
| 2026-01-29 | Joanne Waldstreicher | Director | A | — | — |
| 2026-01-29 | BERTRAM L SCOTT | Director | A | — | — |
| 2026-01-29 | TIMOTHY M RING | Director | A | — | — |
| 2026-01-29 | Christopher Ian Montague Jones | Director | A | — | — |
| 2026-01-29 | Robert Luther Huffines | Director | A | — | — |
| 2026-01-29 | William M Brown | Director | A | — | — |
| 2026-01-29 | GREGORY HAYES | Director | A | — | — |
| 2026-01-29 | Carrie L Byington | Director | A | — | — |
| 2026-01-29 | R ANDREW ECKERT | Director | A | — | — |
| 2026-01-29 | Jeffrey William Henderson | Director | A | — | — |
| 2026-01-28 | Michael Feld | EVP, CRO & Pres. Life Sciences | Sell | — | — |
| 2026-01-23 | Pamela L. Spikner | SVP Controller & CAO | F | — | — |
| 2026-01-16 | Michael David Garrison | EVP & Pres Med.Essntl&BioPharm | MIXED | — | — |
| 2026-01-06 | David Shan | EVP and Chief ISC Officer | F | — | — |
| 2025-12-29 | Michael Feld | EVP, CRO & Pres. Life Sciences | Sell | — | — |
| 2025-12-17 | Michael David Garrison | EVP & Pres Med.Essntl&BioPharm | Sell | — | — |
| 2025-12-02 | Robert Luther Huffines | Director | A | — | — |
| 2025-12-02 | Jacqueline Wright | Director | A | — | — |
| 2025-12-02 | Michael Feld | EVP, CRO & Pres. Life Sciences | Sell | — | — |
| 2025-12-01 | Pamela L. Spikner | SVPController & Chief Acct Off | A | — | — |
| 2025-12-01 | Thomas E Jr Polen | Chairman, CEO and President | MIXED | — | — |
| 2025-12-01 | Bilal Muhsin | EVP & President Connected Care | A | — | — |
| 2025-12-01 | Richard Byrd | EVP & President Interventional | MIXED | — | — |
| 2025-12-01 | Christopher DelOrefice | EVP & Chief Financial Officer | MIXED | — | — |
| 2025-12-01 | Michael Feld | EVP, CRO & Pres. Life Sciences | MIXED | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Chairman, CEO and President | 206,995 | — |
| — | Director | 140,311 | — |
| — | Chairman | 135,101 | — |
| — | Chairman, CEO and President | 125,680 | — |
| — | Vice Chairman | 96,375 | — |
| — | Executive Vice President | 91,944 | — |
| — | Executive Vice President | 80,948 | — |
| — | Director | 61,445 | — |
| — | Executive Vice President | 50,880 | — |
| — | Sr. VP and General Counsel | 49,079 | — |
| — | EVP & President Connected Care | 43,294 | — |
| — | Director | 36,763 | — |
| — | EVP & Chief Financial Officer | 27,227 | — |
| — | Executive Vice President | 27,025 | — |
| — | Director | 24,304 | — |
| — | Director | 24,257 | — |
| — | Director | 24,148 | — |
| — | Director | 24,071 | — |
| — | EVP and Chief People Officer | 23,966 | — |
| — | Director | 22,596 | — |
| — | Director | 22,416 | — |
| — | Director | 22,226 | — |
| — | EVP, Chief Revenue Officer | 20,934 | — |
| — | Director | 20,689 | — |
| — | Senior VP and Controller | 20,552 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the BDX quote page; the site-wide leaderboard is on the insider transactions hub.